| 1 |
2022 |
Rossella Loria, Patrizia Vici, Francesca Sofia Di Lisa, Silvia Soddu, Marcello Maugeri-Saccà, Giulia Bon. Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue, Frontiers in Oncology. 2022; 12: 877380.
https://doi.org/10.3389/fonc.2022.877380 |
| 2 |
2024 |
Parastoo Shahrouzi, Youness Azimzade, Wioletta Brankiewicz, Sugandha Bhatia, David Kunke, Derek Richard, Xavier Tekpli, Vessela N. Kristensen, Pascal H.G. Duijf. 2024;
https://doi.org/10.21203/rs.3.rs-4594599/v1 |
| 3 |
2024 |
Soo-Yeon Hwang, Kyung-Hwa Jeon, Hwa-Jong Lee, Inhye Moon, Sehyun Jung, Seul-Ah Kim, Hyunji Jo, Seojeong Park, Misun Ahn, Soo-Yeon Kwak, Younghwa Na, Youngjoo Kwon. 2024;
https://doi.org/10.7554/eLife.97051.1 |
| 4 |
2024 |
Parastoo Shahrouzi, Youness Azimzade, Wioletta Brankiewicz, Sugandha Bhatia, David Kunke, Derek Richard, Xavier Tekpli, Vessela N. Kristensen, Pascal H.G. Duijf. 2024;
https://doi.org/10.1101/2024.06.18.599481 |
| 5 |
2024 |
Soo-Yeon Hwang, Kyung-Hwa Jeon, Hwa-Jong Lee, Inhye Moon, Sehyun Jung, Seul-Ah Kim, Hyunji Jo, Seojeong Park, Misun Ahn, Soo-Yeon Kwak, Younghwa Na, Youngjoo Kwon. 2024;
https://doi.org/10.1101/2024.03.01.583029 |
| 6 |
2024 |
Soo-Yeon Hwang, Kyung-Hwa Jeon, Hwa-Jong Lee, Inhye Moon, Sehyun Jung, Seul-Ah Kim, Hyunji Jo, Seojeong Park, Misun Ahn, Soo-Yeon Kwak, Younghwa Na, Youngjoo Kwon. 2024;
https://doi.org/10.7554/eLife.97051.2 |
| 7 |
2024 |
Luying Xu, Yuxin Xie, Qiheng Gou, Rui Cai, Rong Bao, Yucheng Huang, Ruisi Tang. HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future, Frontiers in Pharmacology. 2024; 15: 1446414.
https://doi.org/10.3389/fphar.2024.1446414 |
| 8 |
2024 |
Soo-Yeon Hwang, Kyung-Hwa Jeon, Hwa-Jong Lee, Inhye Moon, Sehyun Jung, Seul-Ah Kim, Hyunji Jo, Seojeong Park, Misun Ahn, Soo-Yeon Kwak, Younghwa Na, Youngjoo Kwon. 2024;
https://doi.org/10.7554/eLife.97051 |
